Department of Otorhinolaryngology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, People's Republic of China.
Department of Nanchong Vocational College of Science and Technology, Nanchong, 637200, People's Republic of China.
Sci Rep. 2024 Feb 18;14(1):4021. doi: 10.1038/s41598-024-54501-2.
Allergic rhinitis (AR) remains a major health problem worldwide. Compared with traditional oral drugs, nasal administration avoids first-pass metabolism and achieve faster and more effective efficacy. In this study, we used the ion crosslinking method to prepare quercetin-chitosan nasal adaptive nanomedicine (QCS) delivery system and evaluated in the treatment of allergic rhinitis mice models. The obtained positively charged nanoparticles with a particle size of 229.2 ± 0.2 nm have excellent characteristics in encapsulation efficiency (79.604%), drug loading rate (14.068%), drug release (673.068 μg) and stability(> 7 days). Excitingly, QCS treatment significantly reduced the number of sneezing and nasal rubbing events in AR mice, while reducing the levels of inflammatory factors such as immunoglobulin E (IgE), interleukin (IL)-17, tumor necrosis factor (TNF)-α, and (IL)-6 to alleviate AR symptoms. Hematoxylin-eosin (HE) staining also showed the damaged nasal mucosa was improved. These experimental results suggest that QCS can effectively suppress allergic inflammation in a mouse model and hold promise as a therapeutic option for allergic rhinitis.
变应性鼻炎（AR）仍然是全世界的一个主要健康问题。与传统的口服药物相比，鼻内给药可避免首过代谢，达到更快、更有效的疗效。在这项研究中，我们使用离子交联法制备槲皮素-壳聚糖鼻用自适应纳米药物（QCS）传递系统，并在过敏性鼻炎小鼠模型中进行了评估。得到的带正电荷的纳米粒子粒径为 229.2 ± 0.2nm，具有出色的包封效率（79.604%）、载药量（14.068%）、药物释放（673.068μg）和稳定性（>7 天）。令人兴奋的是，QCS 治疗可显著减少 AR 小鼠的打喷嚏和鼻摩擦次数，同时降低免疫球蛋白 E（IgE）、白细胞介素（IL）-17、肿瘤坏死因子（TNF）-α和（IL）-6 等炎症因子的水平，从而缓解 AR 症状。苏木精-伊红（HE）染色也显示受损的鼻黏膜得到改善。这些实验结果表明，QCS 可有效抑制小鼠模型中的过敏炎症，有望成为治疗变应性鼻炎的一种选择。
